High dose rate endorectal brachytherapy as a neoadjuvant treatment for patients with resectable rectal cancer.
In the era of total mesorectal surgery, the issue of radiation toxicity is raised. A novel endocavitary brachytherapy technique was tested as a neoadjuvant treatment for patients with resectable rectal cancer. The objectives of the study were to evaluate the treatment-related toxicity and effects on local recurrence. A dose of 26 Gy was prescribed to the gross tumour volume and intramesorectal deposits seen on magnetic resonance imaging and given over four daily treatments, using the high dose rate delivery system followed by surgery 6-8 weeks later. The study included 93 T3, four T4 and three T2 tumours. Acute proctitis of grade 2 was observed in all patients, but one required transfusion. At a median follow-up time of 60 months, the 5-year actual local recurrence rate was 5%, disease-free survival was 65%, and overall survival was 70%. High dose rate endorectal brachytherapy seems to prevent local recurrence and has a favourable toxicity pattern compared with external beam radiotherapy.
Vuong
T
T
Department of Radiation Oncology, McGill University Health Centre, Montreal, Quebec, Canada. te.vuong@muhc.mcgill.ca
Devic
S
S
Podgorsak
E
E
D001918:Brachytherapy / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D020360:Neoadjuvant Therapy / Q000379:methods*; D011879:Radiotherapy Dosage; D012004:Rectal Neoplasms / Q000532:radiotherapy* / Q000601:surgery*; D016896:Treatment Outcome